Unlocking Insights in Autoimmune diseases treatment
Janus Kinase Inhibitors (JAKi)

JULY 2024

Knowledge for better health

HMR

Our latest Autoimmune diseases study features an extensive and representative cohort, with **over 26.500 patients** in MAT March 2024, of whom **1.271 were treated with JAKi**, ensuring robust and reliable data.

The complete study evaluates the entire Autoimmune diseases treatment market, providing the following analyses:

- **Therapeutic line analysis:** patient distribution across treatment lines in each therapeutic area (Rheumatology, Gastroenterology, Dermatology and External patients), enables informed decisions about the most appropriate and cost-effective treatment options, leading to improved patient outcomes and optimized resource allocation.

- **Patient dynamics:** Reveal movement patterns (new patients, switch dynamics...), uncovering trends and identifying strategic opportunities.

- **Therapeutic class Analysis:** Market analysis by therapeutic class, increasing granularity and facilitating benchmarking within the class.

Rheumatology

**MAT March 2024**

The complete study comprises:

8.283 total patients with Autoimmune diseases treated in Rheumatology specialty

793 patients treated with JAKi

In the **JAKi submarket** the following results were obtained:

- Xeljanz® holds the highest share with 35,2%

- Most patients are in the age range of 40-59 years (46,5%)

- Within this specialty, JAKi are primarily used as second-line therapy (36,8%)

Patient share[1]

35,2%	34,4%	29,8%	0,6%

■ Xeljanz®   ■ Rinvoq®   ■ Olumiant®   ■ Jyseleca®

1. Comissão Nacional de Farmácia e Terapêutica. Medicamentos biológicos utilizados em doenças reumáticas, psoríase e doença inflamatória intestinal: Linhas de tratamento e alternativas terapêuticas. Lisboa, 2023.

Age Distribution

0-14	15-39	40-59	60-79	80+
0,4%	8,1%	46,5%	42,5%	2,6%

Therapeutic Line Distribution

1st	2nd	3rd	+ 4th
35,3%	36,8%	16,4%	11,5%

HMR

Gastroenterology

**MAT March 2024**

The complete study comprises:

7.758 total patients with Autoimmune diseases treated in Gastroenterology specialty

227 patients treated with JAKi

In the **JAKi submarket** the following results were obtained:

- Xeljanz® holds the highest share with 59,0%

- Most patients are in the age range of 15-39 years (48,1%)

- Within this specialty, JAKi are primarily used as second-line therapy (32,6%)

Patient share[1]

| 59,0%	41,0%

Xeljanz®   Rinvoq®

1. Comissão Nacional de Farmácia e Terapêutica. Medicamentos biológicos utilizados em doenças reumáticas, psoríase e doença inflamatória intestinal: Linhas de tratamento e alternativas terapêuticas. Lisboa, 2023.

Age Distribution

0-14	15-39	40-59	60-79	80+
0,0%	48,1%	36,9%	13,7%	1,3%

Therapeutic Line Distribution

1st	2nd	3rd	+ 4th
15,5%	32,6%	21,3%	30,5%

HMR

4

External

The complete study comprises:

5.938 total patients with Autoimmune diseases whose prescription comes from the private sector

277 patients treated with JAKi

In the **JAKi submarket** the following results were obtained:

- Rinvoq® holds the highest share with 41,2%
- Most patients are in the age range of 40-59 years (49,6%)
- Within this specialty, JAKi are primarily used as first-line therapy (57,0%)

Patient share[1]

Rinvoq® 41,2%	Xeljanz® 35,0%	Olumiant® 23,8%

Legend: ■ Rinvoq® ■ Xeljanz® ■ Olumiant®

1. Comissão Nacional de Farmácia e Terapêutica. Medicamentos biológicos utilizados em doenças reumáticas, psoríase e doença inflamatória intestinal: Linhas de tratamento e alternativas terapêuticas. Lisboa, 2023.

Age Distribution

Age range	Percentage
0-14	0,0%
15-39	10,1%
40-59	49,6%
60-79	38,8%
80+	1,4%

Therapeutic Line Distribution

Line	Percentage
1st	57,0%
2nd	27,8%
3rd	9,7%
+ 4th	5,4%

HMR

Technical File

SCOPE

Obtain an overview of the population receiving treatment for Autoimmune diseases in Portugal, evaluating the performance of individual drugs within the class of Janus Kinase Inhibitors for autoimmune diseases.

PERIOD

April 2023 – March 2024

MEASURES & METRICS

Patient-Level Hospital Consumption Records from the HMR Hospital Database, compliant with anonymisation requirements.

MARKET SELECTION & ASSUMPTIONS

Drugs used to treat Autoimmune diseases within - ATC Class "L04 – Immunosupressants"